<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Calcium-channel Blockers: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int466-calcium-channel-blockers.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int466-calcium-channel-blockers.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int466-calcium-channel-blockers.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int465-calcium-salts.htm" title="Previous: Calcium Salts">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int468-diltiazem.htm" title="Next: Diltiazem">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Calcium-channel Blockers</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Calcium-channel Blockers</strong> has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int21-aldesleukin.htm">Aldesleukin</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>aldesleukin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td class="cAI"><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>alpha-blockers</span> <span>, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin</span>  </p></td><td></td></tr><tr><td><a href="bnf_int681-alprostadil.htm">Alprostadil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>alprostadil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>general anaesthetics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>antipsychotics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>baclofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>calcium-channel blockers</span> <span>possibly inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>calcium-channel blockers</span> <span>possibly inhibited by</span> <span>clarithromycin</span> <span>(increased risk of side-effects)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>hypotensive effect of </span> <span>calcium-channel blockers</span> <span>antagonised by</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>calcium-channel blockers</span> <span>possibly inhibited by</span> <span>erythromycin</span> <span>(increased risk of side-effects)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int50-isoflurane.htm">Isoflurane</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>isoflurane</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>negative inotropic effect possibly increased when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>levodopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>MAOIs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td><p><span>possible increased risk of bradycardia when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>mefloquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>methyldopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int806-moxisylyte.htm">Moxisylyte</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>moxisylyte</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td><p><span></span> <span>calcium-channel blockers</span> <span>possibly enhance effects of</span> <span>non-depolarising muscle relaxants</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td><p><span>hypotensive effect of </span> <span>calcium-channel blockers</span> <span>antagonised by</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>hypotensive effect of </span> <span>calcium-channel blockers</span> <span>antagonised by</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>effects of </span> <span>calcium-channel blockers</span> <span>probably reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>calcium-channel blockers</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>calcium-channel blockers</span> <span>possibly inhibited by</span> <span>telithromycin</span> <span>(increased risk of side-effects)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>calcium-channel blockers</span> <span>possibly increase plasma concentration of</span> <span>theophylline</span> <span>(enhanced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>calcium-channel blockers</span> <span>given with</span> <span>tizanidine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Diltiazem</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>diltiazem</span> <span>inhibits metabolism of</span> <span>alfentanil</span> <span>(risk of prolonged or delayed respiratory depression)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of bradycardia, AV block and myocardial depression when </span> <span>diltiazem</span> <span>given with</span> <span>amiodarone</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span></span> <span>diltiazem</span> <span>possibly increases plasma concentration of</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span>plasma concentration of both drugs may increase when </span> <span>diltiazem</span> <span>given with</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>diltiazem</span> <span>increased by</span> <span>atazanavir</span> <span>(reduce dose of <span>diltiazem</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>atorvastatin</span> <span>—possible increased risk of myopathy</span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td class="cAI"><p><span>increased risk of AV block and bradycardia when </span> <span>diltiazem</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>enhances effects of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int940-cilostazol.htm">Cilostazol</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>cilostazol</span> <span>(consider reducing dose of <span>cilostazol</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int618-dantrolene.htm">Dantrolene</a></td><td><p><span>possible increased risk of ventricular arrhythmias when </span> <span>diltiazem</span> <span>given with intravenous</span> <span>dantrolene</span> <span>—manufacturer of <span>diltiazem</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of bradycardia and myocardial depression when </span> <span>diltiazem</span> <span>given with</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int975-dutasteride.htm">Dutasteride</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>dutasteride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>diltiazem</span> <span>reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1202-fingolimod.htm">Fingolimod</a></td><td class="cAI"><p><span>possible increased risk of bradycardia when </span> <span>diltiazem</span> <span>given with</span> <span>fingolimod</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int247-imipramine.htm">Imipramine</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>imipramine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>neurotoxicity may occur when </span> <span>diltiazem</span> <span>given with</span> <span>lithium</span> <span>without increased plasma concentration of <span>lithium</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>methylprednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>diltiazem</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span>plasma concentration of both drugs may increase when </span> <span>diltiazem</span> <span>given with</span> <span>nifedipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>but also effect of <span>diltiazem</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>ranolazine</span> <span>(consider reducing dose of <span>ranolazine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>diltiazem</span> <span>accelerated by</span> <span>rifampicin</span> <span>(plasma concentration significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>simvastatin</span> <span>—possible increased risk of myopathy</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>caution with </span> <span>diltiazem</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span></span> <span>diltiazem</span> <span>increases plasma concentration of</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Verapamil</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span></span> <span>verapamil</span> <span>possibly increases plasma concentration of</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>aliskiren</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of bradycardia, AV block and myocardial depression when </span> <span>verapamil</span> <span>given with</span> <span>amiodarone</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td class="cAI"><p><span>hypotensive effect of </span> <span>verapamil</span> <span>enhanced by</span> <span>general anaesthetics</span> <span>(also AV delay)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span></span> <span>verapamil</span> <span>possibly increases plasma concentration of</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of </span> <span>verapamil</span> <span>possibly increased by</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td class="cAI"><p><span>asystole, severe hypotension and heart failure when </span> <span>verapamil</span> <span>given with</span> <span>beta-blockers</span> <span>(see under Verapamil hydrochloride, <a title="monograph: Verapamil hydrochloride" href="PHP1372-verapamil-hydrochloride.htm">section 2.6.2</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>enhances effects of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>possibly increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>(reduce dose of <span>dabigatran etexilate</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int618-dantrolene.htm">Dantrolene</a></td><td><p><span>manufacturer of </span> <span>verapamil</span> <span>advises avoid concomitant use of intravenous</span> <span>dantrolene</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span> <span>verapamil</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span>, also increased risk of AV block and bradycardia</span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of myocardial depression and asystole when </span> <span>verapamil</span> <span>given with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int506-doxorubicin.htm">Doxorubicin</a></td><td><p><span></span> <span>verapamil</span> <span>possibly increases plasma concentration of</span> <span>doxorubicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of bradycardia and myocardial depression when </span> <span>verapamil</span> <span>given with</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int975-dutasteride.htm">Dutasteride</a></td><td><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>dutasteride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span>plasma concentration of both drugs may increase when </span> <span>verapamil</span> <span>given with</span> <span>everolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>verapamil</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1202-fingolimod.htm">Fingolimod</a></td><td class="cAI"><p><span>possible increased risk of bradycardia when </span> <span>verapamil</span> <span>given with</span> <span>fingolimod</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>increased risk of myocardial depression and asystole when </span> <span>verapamil</span> <span>given with</span> <span>flecainide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>verapamil</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int247-imipramine.htm">Imipramine</a></td><td><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>imipramine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>neurotoxicity may occur when </span> <span>verapamil</span> <span>given with</span> <span>lithium</span> <span>without increased plasma concentration of <span>lithium</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>verapamil</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td><p><span></span> <span>verapamil</span> <span>enhances effects of</span> <span>non-depolarising muscle relaxants</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>effects of </span> <span>verapamil</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>ranolazine</span> <span>(consider reducing dose of <span>ranolazine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>verapamil</span> <span>accelerated by</span> <span>rifampicin</span> <span>(plasma concentration significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>verapamil</span> <span>given with</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span> <span>verapamil</span> <span>given with</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>verapamil</span> <span>significantly reduced by</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td><p><span>plasma concentration of </span> <span>verapamil</span> <span>reduced by</span> <span>sulfinpyrazone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>verapamil</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>verapamil</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>caution with </span> <span>verapamil</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>verapamil</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span>(enhanced effect)</span>  </p></td><td></td></tr></tbody></table><p><strong>Calcium-channel Blockers (dihydropyridines)</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span> <span>dihydropyridines</span> <span>probably reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>metabolism of </span> <span>dihydropyridines</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>metabolism of </span> <span>dihydropyridines</span> <span>possibly inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Amlodipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>amlodipine</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>amlodipine</span> <span>given with</span> <span>sildenafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>amlodipine</span> <span>given with</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span> <span>amlodipine</span> <span>possibly reduced by</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>plasma concentration of </span> <span>amlodipine</span> <span>increased by</span> <span>telaprevir</span> <span>(consider reducing dose of <span>amlodipine</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>Felodipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span> <span>felodipine</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>felodipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>felodipine</span> <span>inhibited by</span> <span>itraconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>felodipine</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>effects of </span> <span>felodipine</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>felodipine</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>caution with </span> <span>felodipine</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Isradipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span> <span>isradipine</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>isradipine</span> <span>increased by</span> <span>cimetidine</span> <span>(halve dose of <span>isradipine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>isradipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>manufacturer of </span> <span>isradipine</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span> <span>isradipine</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>isradipine</span> <span>possibly accelerated by</span> <span>rifampicin</span> <span>(possible significantly reduced plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Lacidipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>lacidipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Lercanidipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>combination of </span> <span>lercanidipine</span> <span>with</span> <span>ciclosporin</span> <span>may increase plasma concentration of either drug (or both)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>lercanidipine</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>manufacturer of </span> <span>lercanidipine</span> <span>advises avoid concomitant use with</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>lercanidipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>manufacturer of </span> <span>lercanidipine</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>manufacturer of </span> <span>lercanidipine</span> <span>advises avoid concomitant use with</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span>absorption of </span> <span>lercanidipine</span> <span>increased by</span> <span>midazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>manufacturer of </span> <span>lercanidipine</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Nicardipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span> <span>nicardipine</span> <span>probably reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>nicardipine</span> <span>increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>nicardipine</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>nicardipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>nicardipine</span> <span>possibly accelerated by</span> <span>rifampicin</span> <span>(possible significantly reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>nicardipine</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>caution with </span> <span>nicardipine</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Nifedipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td class="cAI"><p><span>possible severe hypotension and heart failure when </span> <span>nifedipine</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span> <span>nifedipine</span> <span>probably reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>plasma concentration of </span> <span>nifedipine</span> <span>possibly increased by</span> <span>ciclosporin</span> <span>(increased risk of toxicity including gingival hyperplasia)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>nifedipine</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>plasma concentration of both drugs may increase when </span> <span>nifedipine</span> <span>given with</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>nifedipine</span> <span>increases plasma concentration of</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>metabolism of </span> <span>nifedipine</span> <span>possibly inhibited by</span> <span>fluoxetine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>nifedipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int265-insulin.htm">Insulin</a></td><td><p><span>glucose tolerance occasionally impaired when </span> <span>nifedipine</span> <span>given with</span> <span>insulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int608-magnesium-parenteral.htm">Magnesium (parenteral)</a></td><td class="cAI"><p><span>profound hypotension reported with concomitant use of </span> <span>nifedipine</span> <span>and</span> <span>parenteral magnesium</span> <span>in pre-eclampsia</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1125-micafungin.htm">Micafungin</a></td><td><p><span>plasma concentration of </span> <span>nifedipine</span> <span>increased by</span> <span>micafungin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>nifedipine</span> <span>accelerated by</span> <span>rifampicin</span> <span>(plasma concentration significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span> <span>nifedipine</span> <span>reduced by</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>nifedipine</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>caution with </span> <span>nifedipine</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>nifedipine</span> <span>given with</span> <span>vardenafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int815-vincristine.htm">Vincristine</a></td><td><p><span></span> <span>nifedipine</span> <span>possibly inhibits metabolism of</span> <span>vincristine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Nimodipine</strong> belongs to <strong>Calcium-channel Blockers</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span> <span>nimodipine</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span>(plasma concentration of <span>nimodipine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>nimodipine</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>manufacturer of </span> <span>nimodipine</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span>(plasma concentration of <span>nimodipine</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span> <span>nimodipine</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span>(plasma concentration of <span>nimodipine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>nimodipine</span> <span>accelerated by</span> <span>rifampicin</span> <span>(plasma concentration significantly reduced)</span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int468-diltiazem.htm" title="Diltiazem">Diltiazem</a></li><li><a href="bnf_int467-verapamil.htm" title="Verapamil">Verapamil</a></li><li id="_bnf_int469-calcium-channel-blockers-dihydropyridines"><a href="bnf_int469-calcium-channel-blockers-dihydropyridines.htm" title="Calcium-channel Blockers (dihydropyridines)">Calcium-channel Blockers (dihydropyridines)</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int465-calcium-salts.htm">Previous: Calcium Salts</a> | <a class="top" href="bnf_int466-calcium-channel-blockers.htm#">Top</a> | <a accesskey="]" href="bnf_int468-diltiazem.htm">Next: Diltiazem</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>